1-13 of 13
Lisa Rojkjaer
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

R289, a Dual Irak 1/4 Inhibitor, in Patients with Relapsed/Refractory (R/R) Lower-Risk Myelodysplastic Syndrome (LR-MDS): Initial Results from a Phase 1b Study

Guillermo Garcia-Manero, Yazan F Madanat, Mikkael A. Sekeres, Hetty E. Carraway, Mike Cusnir, James McCloskey, Kiran Naqvi, Gary J. Schiller, Lucy Yan, Toufigh Gordi, Lisa Rojkjaer, Lewis R. Silverman
Journal: Blood
Blood (2024) 144 (Supplement 1): 4595.
https://doi.org/10.1182/blood-2024-206096
Published: 2024
Journal Articles

Nanatinostat (Nstat) and Valganciclovir (VGCV) in Relapsed/Refractory (R/R) Epstein-Barr Virus-Positive (EBV + ) Lymphomas: Final Results from the Phase 1b/2 VT3996-201 Study

Bradley M. Haverkos, Onder Alpdogan, Robert Baiocchi, Jonathan E Brammer, Tatyana A. Feldman, Marcelo Capra, Elizabeth A Brem, Santosh M Nair, Phillip Scheinberg, Juliana Pereira, Leyla Shune, Erel Joffe, Afton Katkov, Robert McRae, Ivor Royston, Lisa Rojkjaer, Pierluigi Porcu
Journal: Blood
Blood (2021) 138 (Supplement 1): 623.
https://doi.org/10.1182/blood-2021-152603
Published: 2021
Journal Articles

Oral Nanatinostat (Nstat) and Valganciclovir (VGCV) in Patients with Recurrent Epstein-Barr Virus (EBV)-Positive Lymphomas: Initial Phase 2 Results

Pierluigi Porcu, MD, Bradley Haverkos, MD MPH, MS, Onder Alpdogan, MD, Robert Baiocchi, MD PhD, Jonathan E Brammer, MD, Tatyana A. Feldman, MD, Marcelo Capra, MD PhD, Elizabeth A Brem, MD, Phillip Scheinberg, MD, Juliana Pereira, MD PhD, Leyla Shune, MD, Afton Katkov, MSc, Robert McRae, Lisa Rojkjaer, MD, Ivor Royston, MD, Douglas V. Faller, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 7–8.
https://doi.org/10.1182/blood-2020-140843
Published: 2020
Journal Articles

LYMRIT 37-01: A Phase I/II Study of 177 lu-Lilotomab Satetraxetan (Betalutin ® ) Antibody-Radionuclide-Conjugate (ARC) for the Treatment of Relapsed Non-Hodgkin's Lymphoma (NHL) — Analysis with 6-Month Follow-up

Arne Kolstad, MD PhD, Ulf Madsbu, MD, Matthew Beasley, MD, Michael Bayne, MD, Tim M. Illidge, MDPhD, Noelle O'Rourke, MD, Ingemar Lagerlöf, MD, Roman Hajek, MD PhD, Wojciech Jurczak, MD PhD, Ella Willenbacher, MD, Unn Merete Fagerli, MD PhD, Aleš Obr, MD, Johan Blakkisrud, MSc, Ayca Muftuler Løndalen, MD, Lisa Rojkjaer, MD, Åse Østengen, Nils Bolstad, MD, Signe Spetalen, MD, Martin Erlanson, MD PhD, Renate Galleberg, MD, Stine Nygaard Rudå, Harald Holte, Jr., MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2879.
https://doi.org/10.1182/blood-2018-99-110555
Published: 2018
Journal Articles

177 Lu-Lilotomab Satetraxetan, a Novel CD37-Targeted Antibody-Radionuclide Conjugate in Relapsed Non-Hodgkin's Lymphoma (NHL): Updated Results of an Ongoing Phase I/II Study (LYMRIT 37-01)

Arne Kolstad, MD PhD, Ulf Madsbu, MD, Matthew Beasley, MD, Michael Bayne, MD, Tim M. Illidge, MDPhD, Noelle O'Rourke, MD, Ingemar Lagerlöf, MD, Roman Hájek, MD, Wojciech Jurczak, PhDMD, Ella Willenbacher, MD, Johan Blakkisrud, MSc, Ayca Muftuler Løndalen, MD, Lisa Rojkjaer, MD, Laurie Baylor Curtis, MSc, Marianne Bloma, MSc, Simon Turner, PhD, Nils Bolstad, MD, Signe Spetalen, MD, Martin Erlanson, MD PhD, Unn Merete Fagerli, MD, Renate Galleberg, MD, Stine Nygaard Rudå, Harald Holte
Journal: Blood
Blood (2017) 130 (Supplement 1): 2769.
https://doi.org/10.1182/blood.V130.Suppl_1.2769.2769
Published: 2017
Journal Articles

Efficacy and Safety of Deferasirox (Exjade ® ) with up to 4.5 Years of Treatment in Patients with Thalassemia Major: A Pooled Analysis

Maria Domenica Cappellini, Renzo Galanello, Antonio Piga, Alan Cohen, Antonis Kattamis, Yesim Aydinok, Paul Williamson, Lisa Rojkjaer, John B Porter
Journal: Blood
Blood (2008) 112 (11): 5411.
https://doi.org/10.1182/blood.V112.11.5411.5411
Published: 2008
Journal Articles

Cumulative Efficacy and Safety of 5-Year Deferasirox (Exjade ® ) Treatment in Pediatric Patients with Thalassemia Major: A Phase II Multicenter Prospective Trial

Antonio Piga, Kamila Kebaili, Renzo Galanello, Valentine Jehl, Corinne Rebischung, Henry Maseruka, Lisa Rojkjaer, Gian Luca Forni
Journal: Blood
Blood (2008) 112 (11): 5413.
https://doi.org/10.1182/blood.V112.11.5413.5413
Published: 2008
Journal Articles

Switching from Deferoxamine (Desferal ® , DFO) to Deferasirox (Exjade ® ) Maintains Effective Control of Iron Levels in Patients with Thalassemia Major (TM)

Maria Domenica Cappellini, Antonis Kattamis, Christos Kattamis, John B Porter, John M Ford, Martha Rodriguez, Lisa Rojkjaer, Antonio Piga
Journal: Blood
Blood (2008) 112 (11): 5416.
https://doi.org/10.1182/blood.V112.11.5416.5416
Published: 2008
Journal Articles

Safety of Deferasirox (Exjade ® ) in Patients with Transfusion-Dependent Anemias and Iron Overload Who Achieve Serum Ferritin Levels <1000 Ng/Ml during Long-Term Treatment

John B Porter, Antonio Piga, Alan Cohen, John M Ford, Janet Bodner, Lisa Rojkjaer, Maria Domenica Cappellini
Journal: Blood
Blood (2008) 112 (11): 5423.
https://doi.org/10.1182/blood.V112.11.5423.5423
Published: 2008
Journal Articles

Deferasirox (Exjade ® ) in Pediatric Patients with β-Thalassemia: Update of 4.7-Year Efficacy and Safety from Extension Studies

Antonio Piga, Gian Luca Forni, Antonis Kattamis, Christos Kattamis, Yesim Aydinok, Martha Rodriguez, Lisa Rojkjaer, Renzo Galanello
Journal: Blood
Blood (2008) 112 (11): 3883.
https://doi.org/10.1182/blood.V112.11.3883.3883
Published: 2008
Journal Articles

Deferasirox (Exjade ® ), the Once-Daily Oral Iron Chelator, Demonstrates Safety and Efficacy in Patients with Sickle Cell Disease (SCD): 3.5-Year Follow-up.

Elliott Vichinsky, Thomas Coates, Alexis A Thompson, Françoise Bernaudin, Martha Rodriguez, Lisa Rojkjaer, Matthew M Heeney
Journal: Blood
Blood (2008) 112 (11): 1420.
https://doi.org/10.1182/blood.V112.11.1420.1420
Published: 2008
Journal Articles

Effect of Deferasirox on Midazolam Pharmacokinetics.

Caroline Arrowsmith-Bensasson, Lisa Rojkjaer, Venkat Sethuraman, Andrej Skerjanec
Journal: Blood
Blood (2007) 110 (11): 3826.
https://doi.org/10.1182/blood.V110.11.3826.3826
Published: 2007
Journal Articles

Deferasirox Reduces Iron Overload in a Murine Model of Juvenile Hemochromatosis.

Hanspeter Nick, Peter Allegrini, Lucy Fozard, Ursula Junker, Lisa Rojkjaer, Rishard Salie, Vera Niederkofler, Terrence O’Reilly
Journal: Blood
Blood (2006) 108 (11): 1772.
https://doi.org/10.1182/blood.V108.11.1772.1772
Published: 2006